Abstract
The article describes a successful experience of using high-dose rate brachytherapy (192Ir) in patients with local recurrence of hormone-resistant prostate cancer. High-dose rate brachytherapy allowed to achieve local biochemical control of prostate cancer without toxicity to pelvic organs, thus, maintaining the quality of life.
Publisher
Publishing House ABV Press
Subject
Urology,Nephrology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery
Reference13 articles.
1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. C A Cancer J Clin 2014;64:9–29. DOI: 10.3322/caac.21208. PMID: 24399786.
2. Jung K.W., Won Y.J., Kong H.J. et al. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat 2013;45(1):1–14. DOI: 10.4143/crt.2013.45.1.1. PMID: 23613665.
3. Scher H.I., Halabi S., Tannock I. et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26(7):1148–59. DOI: 10.1200/JCO.2007.12.4487. PMID: 18309951.
4. Huggins C., Hodges C.V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293–7. [Reprinted in: J Urol 2002;168(1):9–12. PMID: 12050481.]
5. Luo J., Beer T.M., Graff J.N. Treatment of nonmetastatic castration-resistant prostate cancer. Oncology 2016;30(4):336–44. PMID: 27085332.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献